PrestigeBrands



Review of Second Quarter FY 16 Results November 5, 2015

Safe Harbor Disclosure

This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's product expansion and development plans, investments in brand building and marketing, debt reduction and future financing capacity, consumption growth and strength of the Company's brands, M&A strategy and market activity, future financial performance, and creation of shareholder value. Words such as "continue," "will," "expect," "project," "anticipate," "likely," "estimate," "may," "should," "could," "would," and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company's expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the inability to identify and consummate future acquisitions at attractive valuations, the failure to successfully commercialize new products, the severity of the cold and flu season, the inability of third party suppliers to meet demand, competitive pressures, the effectiveness of the Company's brand building and marketing investments, fluctuating foreign exchange rates, and other risks set forth in Part I, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March 31, 2015 and in Part II, Item 1A. Risk Factors in the Company's Quarterly Report on Form 10-Q for the guarter ended June 30, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise.



Agenda for Today's Discussion

- I. Performance Highlights
- **II.** Financial Overview
- **III. FY 16 Outlook and the Road Ahead**








Solid Q2 Results First Half Results In Line with Expectations

- Q2 consolidated **Revenue** of **\$206.1** million, up **13.7%** versus prior year Q2, and **+17.1%**⁽¹⁾ on a constant currency basis
 - First half consolidated Revenue growth of 21.8%, consistent with prior guidance of +20% to +23% for that period
 - Q2 Organic decline of (0.5)%⁽¹⁾ and first half Organic growth of 1.4%⁽¹⁾, on a constant currency basis
 - Q2 Core OTC + International Revenue growth of 3.0% on a constant currency basis
- Q2 Core OTC consumption growth of 3.6% and first half Core OTC consumption growth of 5.5%
 - 78% of Core OTC portfolio with consumption growth in Q2
 - Continued strength in our biggest brands
 - Consistent and innovative marketing support building long-term brand equity in Core OTC brands
- Adjusted Gross Margin of 58.2%⁽²⁾ versus 57.0% in the prior year Q2, and in-line with 58.4% in Q1
- Adjusted EPS of \$0.60⁽²⁾, up 20.0% versus the prior year Q2
- Strong Free Cash Flow of \$46.2⁽²⁾ million, up 26.4% versus the prior year Q2
- Leverage of ~5.0x⁽³⁾, down from 5.7x at the time of the Insight acquisition



Solid Q2 Results Company on Track to Meet FY2016 Expectations

• Company on track to continue to deliver strong financial performance in FY2016





Continued Core OTC Consumption Growth and Sales Momentum






Source: IRI multi-outlet + C-Store retail dollar sales growth for relevant period. Data reflects retail dollar sales percentage growth versus prior period; FY'16 Organic sales growth presented on a constant currency basis.

Q2 FY 16 Core OTC Growth Broad Based, Led by Largest Brands

Core OTC Portfolio with Consumption Growth in Q2 FY 16

Largest Brands Growing Above Categories



Y/Y Retail Sales % Growth




Core OTC, includes Insight Pharmaceuticals. Source: IRI multi-outlet + C-Store, L-12 period for each quarter.

Source. IRI multi-outlet + C-Store, L-12 period for each quarter.

Data reflects retail dollar sales percentage growth versus prior period;

First Half Investment in Core OTC and International Driving Organic Growth



Monistat Building Momentum One Year After Acquisition; +6% in 1H



The Prestige 4-Part Plan for Monistat Success Began on Day 1

- 1. Re-engage With Health Care Professionals (HCP)
 - Create new educational materials for HCPs
 - Partner with professional detail force and tele-sales reps
- 2. Re-engage With Consumers
 - Capture key consumer insights through targeted consumer research
 - Develop new creative advertising & media plan
 - Build New Digital Marketing and Social Media Outreach Program
 - Create new Women's Health PR Education Initiative
- 3. Re-engage With Retail Customers
 - Maximize shelf impact with new package design and pricing
 - As category leader, share insights and updates with retail partners
- 4. Fill New Product Development Pipeline
 - Extend the brand through NPD and innovation



Source: IRI multi-outlet + C-Store, L-26 period ending October 4, 2015.

Second Quarter FY 16 Results

Women Like Me – Online Support





First Time Yeast Infection Sufferer

Yeast Infections with an Active Lifestyle





Menopause and Yeast Infections

Yeast Infections and Antibiotics or Other Medications





Yeast Infections and Diabetes

Chronic Yeast Infection Sufferers









Little Remedies: Our Core Pediatric Brand Expands With New GI Product



- Expanding Product Offering: Little Remedies expands focus to include products for fast-growing digestive category to treat infant gas and colic
- Multi-Media Marketing Approach: Features first TV campaign ever for digestive brands, a social media initiative providing advice to parents, and an educational outreach to HCPs including sampling
- New Marketing Efforts: Engaging caregivers and HCPs to focus on supporting baby's digestive health



PrestigeBrands

Marketing Strategy

Second Quarter FY 16 Results

11

New GI Product

Expanded Healthcare Solutions

Luden's: A Classic Brand Engaging A New Generation of Consumers



- Revitalized and modernized: Luden's still retains its heritage and reputation for great taste for a new generation
- Marketing and NPD Working Together: Flavor line expansion, new sizes, packaging innovation, consumer insight research, retail promotions, digital marketing and experiential marketing tactics have all contributed to the growth of this brand among a younger generation
- Resulting In: Sales CAGR of +5% in the 5 years it has been with the Prestige family










Key Financial Results for Second Quarter Performance

Solid overall financial performance in the quarter

- Revenue of \$206.1 million, an increase of 13.7%
- Organic Revenue decline of (0.5%)⁽¹⁾ excluding the impact of foreign currency
- Adjusted EPS of \$0.60⁽²⁾, up 20.0%
- Free Cash Flow growth of 26.4% to \$46.2 million⁽²⁾





Dollar values in millions, except per share data.

FY 16 Second Quarter and 1H Consolidated Financial Summary

- Q2 Revenue growth of +13.7%, or +17.1%⁽¹⁾ on a constant currency basis
- Q2 Adjusted Gross Margin of 58.2%⁽²⁾, consistent with full year outlook of 58.0%
- Q2 A&P of 13.5% of Total Revenue, or \$27.9 million, up 11.4% versus PYQ2
- Q2 Adjusted EBITDA Margin of 36.7%⁽²⁾
- Q2 Adjusted EPS of \$0.60, up 20.0%⁽²⁾

justed EPS of \$0.60, up 20.0% ⁽²⁾	3 Months Ended					6 Months Ended					
	Sep '15		Sep '14		% Chg		Sep '15		Sep '14		% Chg
Total Revenue	\$	206.1	\$	181.3	13.7%		\$	398.2	\$	327.0	21.8%
Adj. Gross Margin % Margin		119.9 58.2%		103.3 57.0%	16.1%			232.2 58.3%		185.3 56.7%	25.3%
A&P % Total Revenue		27.9 13.5%		25.0 13.8%	11.4%			54.3 13.6%		44.1 13.5%	23.1%
Adj. G&A % Total Revenue		16.5 <i>8.0%</i>		15.0 8.3%	9.4%			32.6 8.2%		26.9 8.2%	21.3%
Adjusted EBITDA % Margin	\$	75.6 36.7%	\$	63.2 34.9%	19.6%		\$	145.2 36.5%	\$	114.3 <i>34.9%</i>	27.1%
Adjusted Net Income	\$	31.8	\$	26.4	20.6%		\$	59.2	\$	47.9	23.7%
Adjusted Earnings Per Share	\$	0.60	\$	0.50	20.0%		\$	1.12	\$	0.91	23.1%



Dollar values in millions, except per share data. Refer to footnote 2 for all adjusted items above.

Exceptional Free Cash Flow Trends

Cash Flow

	Three Months Ended				Six Months Ended				
	Sep'15		Sep'14		Sep'15		Sep'14		
Net Income - As Reported	\$	31.8	\$	16.5	\$	58.0	\$	33.2	
Depreciation & Amortization		5.7		3.9		11.4		6.8	
Other Non-Cash Operating Items		14.4		8.0		31.5		17.9	
Working Capital		(4.8)		(1.0)		(10.3)		(1.0)	
Operating Cash Flow ⁽⁶⁾	\$	47.1	\$	27.4	\$	90.6	\$	57.1	
Additions to Property and Equipment		(0.9)		(0.9)		(1.7)		(1.4)	
Free Cash Flow ⁽²⁾	\$	46.2	\$	26.5	\$	88.9	\$	55.7	
Acquisition Costs		-		10.0		-		12.4	
Adjusted Free Cash Flow ⁽²⁾	\$	46.2	\$	36.5	\$	88.9	\$	68.1	


Comments

Debt Profile & Financial Compliance:

- Net Debt at 9/30/15 of \$1,481 million comprised of:
 - Cash on hand of \$22 million
 - \$853 million of term loan and revolver
 - \$650 million of bonds
- Leverage ratio⁽³⁾ of ~5.0x
- Acquisition capacity exceeding ~\$550 million



Dollar values in millions.






Staying the Strategic Course to Continue Shareholder Value Creation

Strong Consumption Trends	 Good momentum heading into Q3 Retail environment continues to present headwinds Fx impact larger than anticipated of approx. +\$12MM full year, no impact expected on EPS or FCF
Brand Building	 Continued focus on investment in brand building for FY 16 Invest and innovate in Core OTC brands and international platform Continue to build new product pipeline for the long term
M&A Strategy	 Remain aggressive and disciplined Rapidly de-levering and building meaningful M&A capacity Continue to monitor major company divestiture announcements and opportunities with privately-held assets
Confident in Full FY 16 Outlook	 Revenue growth of +10% to +11% to reflect current Fx rates, 2H +0.5% to +1.5% Adjusted EPS +10% to +13% (\$2.05 to \$2.10)⁽⁷⁾, expect to be at high end of range Free cash flow of \$175MM⁽⁸⁾ or more Continued A&P investment in portfolio





Appendix

- (1) Revenue Growth on a constant currency basis is a Non-GAAP financial measure and is reconciled to its most closely related GAAP financial measure in our earnings release in the "About Non-GAAP Financial Measures" section.
- (2) Adjusted Gross Margin, Adjusted G&A, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted EPS, Free Cash Flow and Adjusted Free Cash Flow are Non-GAAP financial measures and are reconciled to their most closely related GAAP financial measures in our earnings release in the "About Non-GAAP Financial Measures" section.
- (3) Leverage ratio reflects net debt / covenant defined EBITDA.
- (4) Pro forma Net Sales for FY 15 as if Insight and Hydralyte were acquired on April 1, 2014.
- (5) Based on Company's organic long-term plan. Source: Company data.
- (6) Operating cash flow is equal to GAAP net cash provided by operating activities.
- (7) Adjusted EPS for FY 16 is a projected Non-GAAP financial measure, is reconciled to projected GAAP EPS in our earnings release in the "About Non-GAAP Financial Measures" section and is calculated based on projected GAAP EPS of \$2.00 to \$2.05 plus \$0.05 of cost associated with term loan refinancing and CEO retirement totaling \$2.05 to \$2.10.
- (8) Free Cash Flow for FY 16 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Net Cash Provided by Operating Activities in our earnings release in the "About Non-GAAP Financial Measures" section and is calculated based on projected Net Cash Provided by Operating Activities of \$181 million less projected capital expenditures of \$6 million.

